Sedana Medical AB Interim report January-March 2022
First patient enrolled in US clinical programFirst quarter 2022 · Net sales totalled MSEK 34 (45), equivalent to a decrease of 25% compared to the first quarter of 2021. At constant exchange rates, sales decreased by 28%. The development is a consequence of a significant decline in ventilated patients in intensive care units. · Gross profit was MSEK 23 (29), equivalent to a margin of 68% (64%). The improved margin is principally due to lower transportation costs and to some extent to a positive market mix. · Earnings before interest, taxes, depreciation and amortisation (EBITDA)